Memorial Hospital Research Laboratories
The Luis Diaz Jr. Lab
Research
Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide.
Featured News
Publications Highlights
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Cercek A, Lumish M, Sinopoli J, Weiss J,..,Diaz LA Jr.. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5. PMID: 35660797, PMCID: PMC9492301.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le DT, Uram JN, Wang H,…,Diaz LA Jr.. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. PMID: 26028255; PMCID: PMC4481136.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr.
Cancer genome landscapes.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW.Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.
Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr.
People
Luis Diaz Jr., MD
Head of the Division of Solid Tumor Oncology; Grayer Family Chair
- Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide.
- MD, University of Michigan
- [email protected]
- Email Address
- 646-888-4641
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Luis Diaz Jr. discloses the following relationships and financial interests:
-
ChromaCode
Equity -
Delfi Diagnostics, Inc.
Equity; Professional Services and Activities (Uncompensated) -
Epitope
Equity; Fiduciary Role / Position -
Innovatus Capital Partners, LLC
Professional Services and Activities -
Johns Hopkins University School of Medicine
Intellectual Property Rights
-
Neophore
Equity; Professional Services and Activities (Uncompensated) -
Quest Diagnostics
Equity; Fiduciary Role / Position -
Seer Biosciences
Equity; Professional Services and Activities -
Zydecom
Equity
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].